The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2023.105505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Vishwas Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Biology and Genetics, Indian Institute of Science, Bengaluru, India. Hauptthemen laut MEDLINE: Receptors, Guanylate Cyclase-Coupled. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, DBT-Wellcome Trust India Alliance, Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
Mutations in receptor guanylyl cyclase C (GC-C) cause severe gastrointestinal disease, including meconium ileus, early onset acute diarrhea, and pediatric inflammatory bowel disease that continues into adulthood. Agonists of GC-C are US Food and Drug Administration-approved drugs for the treatment of constipation and irritable bowel syndrome. Therapeutic strategies targeting GC-C are tested in preclinical mouse models, assuming that murine GC-C mimics human GC-C in its biochemical properties and downstream signaling events. Here, we reveal important differences in ligand-binding affinity and GC activity between mouse GC-C and human GC-C. We generated a series of chimeric constructs of various domains of human and mouse GC-C to show that the extracellular domain of mouse GC-C contributed to log-orders lower affinity of mouse GC-C for ligands than human GC-C. Further, the Vmax of the murine GC domain was lower than that of human GC-C, and allosteric regulation of the receptor by ATP binding to the intracellular kinase-homology domain also differed. These altered properties are reflected in the high concentrations of ligands required to elicit signaling responses in the mouse gut in preclinical models and the specificity of a GC inhibitor towards human GC-C. Therefore, our studies identify considerations in using the murine model to test molecules for therapeutic purposes that work as either agonists or antagonists of GC-C, and vaccines for the bacterial heat-stable enterotoxin that causes watery diarrhea in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Developmental Biology and Genetics, Indian Institute of Science, Bengaluru, India.
- UMR 5248 - Chemistry & Biology of Membranes and Nano-Objects, CNRS - Université de Bordeaux, Institut Européen de Chimie et Biologie, Pessac, France.
- Department of Developmental Biology and Genetics, Indian Institute of Science, Bengaluru, India. Electronic address: sandhya@iisc.ac.in.
Förderung
- Wellcome Trust
- DBT-Wellcome Trust India Alliance
- Council of Scientific and Industrial Research, India
- Science and Engineering Research Board
- The Wellcome Trust DBT India Alliance
- Department of Science and Technology
Zitieren
APA
Mishra, V., Sharma, K., Bose, A., Maisonneuve, P., & Visweswariah, S. S. (2024). The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105505
Vancouver
Mishra V, Sharma K, Bose A, Maisonneuve P, Visweswariah SS. The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2023.105505
BibTeX
@article{Mishra2024,
author = {Mishra, Vishwas and Sharma, Kritica and Bose, Avipsa and Maisonneuve, Pierre and Visweswariah, Sandhya S},
title = {The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2023.105505}
}
EUVIMED